Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged one to 17 years with diabetes.
from The Medical News http://ift.tt/1vfGxZm
from The Medical News http://ift.tt/1vfGxZm
No comments:
Post a Comment